论文部分内容阅读
目的:观察云芝多糖(PSK)联合XELOX方案在晚期大肠癌化疗中的疗效和不良反应。方法:53名晚期大肠癌患者随机分为对照组(26人)和治疗组(27人)。对照组选用XELOX方案;治疗组在对照组基础上加用云芝多糖胶囊6g/d,连续口服1年以上。至少3个化疗周期后评价疗效。结果:化疗中白细胞减少、血小板减少、手足综合征及消化道不良反应发生率治疗组较对照组低(P<0.05);3个周期后ECOGPS评分,治疗组较对照组身体状况好(P<0.05);治疗组和对照组的治疗有效率分别为55.6%和46.2%,临床获益率分别为81.5%和76.9%,两组近期疗效无统计学差异;中位疾病进展时间(TTP)分别为7.12个月和6.21个月,3年生存率分别为59.3%和30.8%,两组间差异有统计学差异(P值分别为0.024和0.035)。结论:PSK联合XELOX方案能提高远期疗效,提高生活质量,减少不良反应,安全有效。
Objective: To observe the efficacy and adverse reactions of PSK combined with XELOX regimen in the treatment of advanced colorectal cancer. Methods: Fifty-three patients with advanced colorectal cancer were randomly divided into control group (26 patients) and treatment group (27 patients). The control group selected XELOX program; treatment group in the control group plus Coriolus versicolor capsule 6g / d, continuous oral administration of more than 1 year. Evaluation of efficacy after at least 3 cycles of chemotherapy. Results: The incidences of leukopenia, thrombocytopenia, hand-foot syndrome and gastrointestinal adverse reactions in the treatment group were lower than those in the control group (P <0.05). The ECOGPS score of the three cycles was significantly higher in the treatment group than in the control group (P < 0.05). The effective rates of treatment and control group were 55.6% and 46.2%, respectively. The clinical benefit rates were 81.5% and 76.9% respectively. There was no significant difference in the short term efficacy between the two groups. The median time to progression of disease (TTP) For 7.12 months and 6.21 months, the 3-year survival rates were 59.3% and 30.8%, respectively. There was significant difference between the two groups (P = 0.024 and 0.035, respectively). Conclusion: PSK combined with XELOX regimen can improve long-term efficacy, improve quality of life, reduce adverse reactions, and be safe and effective.